bioactivity


Also found in: Medical, Encyclopedia.

bi·o·ac·tiv·i·ty

 (bī′ō-ăk-tĭv′ĭ-tē)
n.
The effect of a given agent, such as a vaccine, upon a living organism or on living tissue.

bi•o•ac•tiv•i•ty

(ˌbaɪ oʊ ækˈtɪv ɪ ti)

n.
any effect on, interaction with, or response from living tissue.
[1970–75]
bi`o•ac′tive, adj.
References in periodicals archive ?
It is critical to fully characterize these compounds to further our understanding of their bioactivity and, ultimately, enable the development of pharmaceuticals.
In the Phase 1 study BLX-883 was safely administered at a clinically relevant dose and demonstrated bioactivity consistent with Intron(R) A, a currently marketed alfa interferon used as a comparator.
The laboratory experiment demonstrated that the enhanced bioactivity of the crude white carrot extract must be due to these non-pigmented phytochemicals.
The study resulted in the identification of biologically active molecules that were structurally distinct from the known compounds, providing an advantage over methods that rely on chemical structure alone for modeling bioactivity.
is a biopharmaceutical company with over 50 patents supporting an extensive library of peptides that are diverse in structure, sequence, and bioactivity.
The new results were consistent with earlier studies of Zeatin and Senetek's lead anti-aging compound Kinetin which suggested that at higher concentrations Zeatin was more effective than Kinetin in certain measures of bioactivity.
Trana Discovery, a drug discovery technology company, today announced that their recently-developed HIV high-throughput screening (HTS) assay designed to identify compounds that inhibit the use of transfer RNA (tRNA) by HIV has the ability to select compounds with anti-HIV bioactivity.
Traditional chemical pegylation sometimes destroys bioactivity if PEG attaches to an amino acid at or near an active site.
The study combined Libraria's Kinase KnowledgeBase and eScreens with GNF's high-quality chemical and bioactivity information to rapidly transition from known chemistries to new chemical space.
Vyta Corp owns a 50% interest in BioAgra, LLC, a joint venture to manufacture and sell Agrastim[R], a purified yeast beta-1,3/1,6-D glucan product with a high bioactivity level of 80% or greater.
Kiadis is collaborating with Unilever by applying its proprietary High Resolution Screening technology to existing complex natural matrices in order to identify high quality bioactivity and structural data on molecules that possess specific bioactivity.
The Platform, called ProCode, can be configured for monoclonal antibody selection, affinity maturation and library generation, for improving solubility and bioactivity of biopharmaceuticals, as well as identification and characterization of protein-protein interactions and discovery of protein drugs.